AN ACT to amend 256.40 (2) (c) 3.; and to create 256.40 (2m) of the statutes;

relating to: reporting of naloxone administration by ambulance service providers.

Analysis by the Legislative Reference Bureau

This bill requires the Department of Health Services to include reports of administration of naloxone or another opioid antagonist by ambulance service providers to its data system that tracks ambulance run data, currently known as the Wisconsin Ambulance Run Data System or WARDS. Current law requires ambulance services providers to require emergency medical responders and emergency medical services practitioners under their supervision to keep a record of each instance of administration of naloxone or another opioid antagonist to an individual who is believed to be undergoing an opioid-related drug overdose and to report this information to DHS in the manner prescribed by DHS.

The bill also requires DHS to submit the records received from the ambulance service providers on administration of naloxone or another opioid antagonist to the prescription drug monitoring program. The bill also requires DHS to consult with the Controlled Substances Board, which administers the PDMP, if necessary to determine a method to facilitate inclusion of the reports from DHS into the PDMP. Currently, the PDMP monitors the dispensing of controlled substances and any other drugs identified by the Controlled Substances Board as having a substantial potential for abuse.
For further information see the state and local fiscal estimate, which will be printed as an appendix to this bill.

The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:

SECTION 1. 256.40 (2) (c) 3. of the statutes is amended to read:

256.40 (2) (c) 3. Submit records under subd. 2. to the department in the manner prescribed by the department through any data system that tracks ambulance run data.

SECTION 2. 256.40 (2m) of the statutes is created to read:

256.40 (2m) The department shall submit to the prescription drug monitoring program under s. 961.385 records of administration of naloxone or another opioid antagonist received under sub. (2) (c) 3. The department shall consult with the controlled substances board if necessary to determine a method to facilitate inclusion of reports of administration of naloxone or another opioid antagonist into the prescription drug monitoring program.

(END)